Clinical Assessment and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
AASLD develops evidence-based practice guidelines and practice guidances which are updated regularly by a committee of hepatology experts and include recommendations of preferred approaches to the diagnostic, therapeutic, and preventive aspects of care.
Practice Guidance
Semaglutide Therapy for Metabolic Dysfunction-Associated Steatohepatitis: November 2025 Updates to AASLD Practice Guidance
AASLD Practice Statement on the Evaluation and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Children
Resmetirom Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease: October 2024 Updates to AASLD Practice Guidance
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Update and Impact of New Nomenclature on the AASLD Clinical Practice Guidance on Nonalcoholic Fatty Liver Disease
AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease [updated 2023]
Supplemental Materials
This AACE guideline provides evidence-based recommendations regarding the diagnosis and management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) to endocrinologists, primary care clinicians, health care professionals, and other stakeholders. It was co-sponsored by AASLD.
Diagnosis and Management of Nonalcoholic Fatty Liver Disease Patient Guideline
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Setting [updated May 2022]
Related Information
SIG Central
SIG Central is an exclusive member forum where you can connect with experts on a variety of topics to help advance the science of hepatology.
Join the Conversation